Work

1218P Long-term survivorship rates among chemotherapy refractory or intolerant advanced esophageal squamous cell carcinoma (aESCC) patients treated with nivolumab (NIVO)

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1336

Authors: J.A. Ajani, D.J. Sharpe, T. De, I. Kim, J.A. Gricar, M. Kurt

Institutions: The University of Texas MD Anderson Cancer Center, PAREXEL International (United Kingdom), PAREXEL International (United States), Bristol-Myers Squibb (United States)

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Bristol-Myers Squibb

OpenAlex ID: W4295828230

FWCI: 0.478

Cites:

Cited by: 3

Related to: 10